Sampirtine

Sampirtine

SCHEMBL1230637

Nc1ccc(Cc2ccc(F)cc2)c(N)n1

nearest known ligand 0.62

Full drug profile on Sugi Atlas →

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.49
IDO1 P14902 1/20 0.40
BACE1 P56817 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
ADCY10 Q96PN6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sampirtine SCHEMBL10569152 0.98 MPO (0.48) MPOIDO1BACE1LOXL2ADCY10
Sampirtine SCHEMBL10569379 0.86 KDM4E (0.42) MPO
SCHEMBL21223703 0.81 MPO (0.49) MPOADCY10
SCHEMBL57463 0.80 MPO (0.56) MPOADCY10
SCHEMBL21223649 0.80 CYP3A4 (0.46) MPO
SCHEMBL10569673 0.79 MPO (0.55) MPOIDO1ADCY10
Hydrochloric Acid SCHEMBL21223749 0.78 CYP3A4 (0.45) MPO
Hydrochloric Acid SCHEMBL10569158 0.78 MPO (0.53) MPOIDO1ADCY10
SCHEMBL10573978 0.73 MPO (0.51) MPOIDO1ADCY10
SCHEMBL8217107 0.72 MPO (0.44) MPOIDO1LOXL2ADCY10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210221784-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITÉ DE STRASBOURG (FR) 2021-07-22 US claimed
EP-3749305-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN Université de Strasbourg (FR) 2020-12-16 EP claimed
CN-111683660-A Compounds and compositions for the treatment of pain 斯特拉斯堡大学 2020-09-18 CN claimed
WO-2019149965-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN UNIVERSITE DE STRASBOURG (FR) 2019-08-08 WO claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-4851420-A ANALGESICS, ANTIPYRETICS ASTA PHARMA AKTIENGESELLSCHAFT (DE) 1989-07-25 US claimed
EP-3782649-B1 BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS ASCENDIS PHARMA AS (DK) 2025-05-14 EP disclosed
US-20230381323-A1 RELEASABLE CONJUGATES FISH & RICHARDSON PC 2023-11-30 US disclosed
US-11786599-B2 Releasable conjugates QUIAPEG PHARMACEUTICALS AB (SE) 2023-10-17 US disclosed
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2023-04-20 US disclosed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO disclosed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US disclosed
US-7115373-B2 Diagnosing allergies via measuring expression of nuclear orphan receptor (NOR-1 receptor) gene; identifying modulators for treating atopic dermatitis GENOX RESEARCH, INC. (JP) 2006-10-03 US disclosed
US-4851420-A ANALGESICS, ANTIPYRETICS ASTA PHARMA AKTIENGESELLSCHAFT (DE) 1989-07-25 US disclosed
EP-0266711-A1 2,6-Diamino-3-halobenzyl-pyridines and process for their preparation as well as their use in pharmaceuticals ASTA Pharma AG (DE) 1988-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210221784-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PAIN ACHE, TRPV1, OPRL1 MPO 155/4885IDO1 2973/4885BACE1 3964/4885
US-20230123784-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 MPO 1900/4885IDO1 1882/4885BACE1 4242/4885
US-20230381323-A1 RELEASABLE CONJUGATES GUSB, ABCB11, UGT2B7 MPO 279/4885IDO1 2709/4885BACE1 1491/4885
US-11786599-B2 Releasable conjugates GUSB, ABCB11, UGT2B7 MPO 279/4885IDO1 2709/4885BACE1 1491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.